Hepatic and metabolic effects of SGLT2 inhibitors in type 2 diabetes and MASLD assessed by metabolomic and lipidomic analysis

Abstract Sodium–glucose cotransporter-2 (SGLT-2) inhibitors show promising hepatic benefits in patients with metabolic dysfunction–associated steatotic liver disease (MASLD); however, their effects on underlying metabolic mechanisms remain unclear. This study included 29 patients with type 2 diabete...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Kenan Moral, Engin Koçak, Sevilay Erdoğan Kablan, Emirhan Nemutlu, Halit Nahit Şendur, Mahinur Cerit, Mehmet Muhittin Yalçın, Gulden Bilican, Mehmet Cindoruk, Tarkan Karakan, Kübra Vardar, Nergiz Ekmen
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Nature Portfolio 2026-05-01
Ráidu:	Scientific Reports
Fáttát:	Hepatic steatosis Lipid Metabolism Aminoacid metabolism Glucose lowering therapy Insulin resistance
Liŋkkat:	https://doi.org/10.1038/s41598-026-44786-w
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!